Marina Theodora van Leeuwen

Dr. Marina Theodora van Leeuwen

UNSW Sydney, Sydney, New South Wales, Australia
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

20 December 2006 in JAMA
Verified
Journal Article
Open access
PDF file
CVClaire Vajdic
Claire Vajdic
SMStephen P. McDonald
Stephen P. McDonald
MMMargaret R. E. McCredie
Margaret R. E. McCredie
MLMarina Theodora van Leeuwen
Marina Theodora van Leeuwen
JSJohn H. Stewart
John H. Stewart
AGAndrew E. Grulich
Andrew E. Grulich
It is widely accepted that immune suppression after organ transplantation is associated with a markedly increased risk of nonmelanoma skin cancer, non-Hodgkin lymphoma, and Kaposi sarcoma.1 Whether other cancers occur at increased rates is controversial, because there have been few long-term population-based cohort studies.

14 May 2009 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
CVClaire Vajdic
Claire Vajdic
MLMarina Theodora van Leeuwen
Marina Theodora van Leeuwen

8 July 2009 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
JSJohn H. Stewart
John H. Stewart
CVClaire Vajdic
Claire Vajdic
MLMarina Theodora van Leeuwen
Marina Theodora van Leeuwen
JAJanaki Amin
Janaki Amin
AWAngela C. Webster
Angela C. Webster
MMMargaret R. E. McCredie
Margaret R. E. McCredie
Background. After transplantation, cancer risk varies from no increase for several common cancers to a many-fold increase for a number of, chiefly virus-associated, cancers. The smaller excess of cancer in dialysis has been less well described, but two studies suggested that impaired immunity might be responsible. Methods. In a population-based cohort study of 28 855 patients who received renal replacement therapy (RRT), we categorized incident cancers as end-stage kidney disease (ESKD) related, immune deficiency related, not related to immune deficiency, or of uncertain status, according to whether they were, or were not, increased in published reports of cancer in ESKD prior to starting RRT, organ transplantation or human immunodeficiency virus infection. Standardized incidence ratios for, and excess burdens of, cancer were calculated for all persons normally resident in Australia starting treatment by dialysis or renal transplantation from 1982 to 2003. Results. The risk for ESKD-related cancers was increased 4-fold in dialysis and during transplant function. For immune deficiency-related cancers, the increase was 1.5 (95% CI 1.3–1.6) times in dialysis, and 5-fold after transplantation. ESKD- or immune deficiency-related cancers contributed to ∼90% of the excess burden of cancer, 48% and 36%, respectively, in dialysis, and 10% and 78% after transplantation. The remaining excess malignancy was contributed by cancers whose relationship with ESKD and immune deficiency is not yet certain. Conclusions. In RRT, the increase in cancer is restricted, largely if not wholly, to cancers with origins in ESKD or related to immune deficiency. For the former, the cancer risk is similar in dialysis and transplantation, but for immune deficiency-related cancers, the relative risk is much greater after transplantation.

11 February 2010 in BMJ
Verified
Journal Article
Open access
PDF file
MLMarina Theodora van Leeuwen
Marina Theodora van Leeuwen
AWAngela C Webster
Angela C Webster
MMMargaret R E McCredie
Margaret R E McCredie
JSJohn H Stewart
John H Stewart
SMStephen P McDonald
Stephen P McDonald
AGAndrew E Grulich
Andrew E Grulich
Objective To compare cancer incidence in kidney transplant recipients during periods of transplant function (and immunosuppression) and after transplant failure (when immunosuppression is ceased or reduced). Design, setting, and participants Nationwide, population based retrospective cohort study of 8173 Australian kidney transplant recipients registered on the Australia and New Zealand Dialysis and Transplant Registry who first received a transplant during 1982-2003. Incident cancers were ascertained using linkage with national cancer registry records. Main outcome measures Cancer-specific standardised incidence ratios for periods of transplant function and for dialysis after transplant failure. Incidence was compared between periods using multivariate incidence rate ratios adjusted for current age, sex, and duration of transplantation. Results All cases of Kaposi’s sarcoma occurred during transplant function. Standardised incidence ratios were significantly elevated during transplant function, but not during dialysis after transplant failure, for non-Hodgkin’s lymphoma, lip cancer, and melanoma. For each of these cancers, incidence was significantly lower during dialysis after transplant failure in multivariate analysis (incidence rate ratios 0.20 (95% CI 0.06 to 0.65) for non-Hodgkin’s lymphoma, 0.04 (0.01 to 0.31) for lip cancer, and 0.16 (0.04 to 0.64) for melanoma). In contrast, standardised incidence ratios during dialysis after transplant failure remained significantly elevated for leukaemia and lung cancer, and cancers related to end stage kidney disease (kidney, urinary tract, and thyroid cancers), with thyroid cancer incidence significantly higher during dialysis after transplant failure (incidence rate ratio 6.77 (2.64 to 17.39)). There was no significant difference in incidence by transplant function for other cancers. Conclusions The effect of immunosuppression on cancer risk is rapidly reversible for some, but not all, cancer types. Risk reversal was mainly observed for cancers with a confirmed infectious cause. Risk of other cancers, especially those related to end stage kidney disease, remained significantly increased after reduction of immunosuppression.

16 July 2009 in Blood
Verified
Journal Article
Open access
PDF file
MLMarina Theodora van Leeuwen
Marina Theodora van Leeuwen
AGAndrew E. Grulich
Andrew E. Grulich
AWAngela C. Webster
Angela C. Webster
MMMargaret R.E. McCredie
Margaret R.E. McCredie
JSJohn H. Stewart
John H. Stewart
CVClaire Vajdic
Claire Vajdic
Non-Hodgkin lymphoma (NHL) incidence is greatly increased after kidney transplantation. NHL risk was investigated in a nationwide cohort of 8164 kidney transplant recipients registered on the Australia and New Zealand Dialysis and Transplant Registry. NHL diagnoses were ascertained using linkage with national cancer registry records. Multivariate Poisson regression was used to compute incidence rate ratios (IRRs) with 95% confidence intervals (CIs) comparing risk by transplant function, and risk factors for early (< 2 years) and late (≥ 2 years) NHL during the first transplantation. NHL occurred in 133 patients. Incidence was strikingly lower after transplant failure and cessation of immunosuppression than during transplant function (IRR, 0.25; 95% CI, 0.08-0.80; P = .019). Early NHL (n = 27) was associated with Epstein-Barr virus (EBV) seronegativity at transplantation (IRR, 4.66; 95% CI, 2.10-10.36, P < .001) and receipt of T cell–depleting antibodies (IRR, 2.39; 95% CI, 1.08-5.30; P = .031). Late NHL (n = 79) was associated with increasing year of age (IRR, 1.02; 95% CI, 1.01-1.04; P = .006), increasing time since transplantation (P < .001), and current use of calcineurin inhibitors (IRR, 3.13; 95% CI, 1.53-6.39; P = .002). These findings support 2 mechanisms of lymphomagenesis, one predominantly of primary EBV infection in the context of intense immunosuppression, and another of dysregulated lymphoid proliferation in a prolonged immunosuppressed state.